Companies / Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc.
Nasdaq: PVLACIK 1583648WAYNE, PA
Financials · FY2023
Ownership
14.4M shares outstanding · as of Jul 31, 2026
Ownership
| Insiders | 1.63% | 235,428 |
| Institutions | 78.24% | 11,273,777 |
| Public float | 20.12% | 2,899,202 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 9
View all →| Insider | % of shares | Shares |
|---|---|---|
Jenkins George MDirector | 1.30% | 187,616 |
Heron Elaine JDirector | 0.33% | 47,812 |
Goin KathleenChief Operating Officer | 0.00% | 0 |
Davis Todd CDirector | — | — |
Kaupinen WesCEOPresident and CEO · Director · 10% owner | — | — |
Kiritsy Christopher PDirector | — | — |
Kline Ashley HartmannChief Commercial Officer | — | — |
Korenberg Matthew ECFO, Treasurer | — | — |
Martini Jeffrey SChief Scientific Officer | — | — |
Institutional holders 156
View all →| Holder | Value | % of shares |
|---|---|---|
| $140.34M | 6.37% | |
| $119.79M | 6.67% | |
| $99.82M | 4.53% | |
| $93.41M | 6.19% | |
| $75.61M | 5.01% | |
| $74.23M | 4.92% | |
| $58.68M | 3.89% | |
| $53.98M | 3.01% | |
| $40.76M | 2.70% | |
| $40.56M | 2.69% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common Stock | $54.91M | +359K +64.27% | 918,357 6.37% of shares | high |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $35.56M | +233K +55.35% | 653,172 4.53% of shares | medium |
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | Exit | Common Stock | $-27.87M | -266K -100.00% | — | medium |
| Q1 2026 as of | Emerald Advisers, LLC 13F manager | New | Common Stock | $20.13M | +162K | 161,500 1.12% of shares | medium |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | New | Common Stock | $16.78M | +135K | 134,600 0.93% of shares | medium |
| Q1 2026 as of | Emerald Mutual Fund Advisers Trust 13F manager | New | Common Stock | $13.19M | +106K | 105,820 0.73% of shares | medium |
| Q1 2026 as of | Millennium Management LLC 13F manager | Add | Common Stock | $11.24M | +90K +2590.98% | 93,646 0.65% of shares | medium |
| Q1 2026 as of | Apis Capital Advisors, LLC 13F manager | New | Common Stock | $11.09M | +89K | 89,000 0.62% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | Passive13G/A | — |
| Biotechnology Value Fund L P | Passive13G/A | — |
| First Light Asset Management, LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| PVLA | Common Stock | 697947109 |